Novel anti‐fibrotic modalities for liver fibrosis: Molecular targeting and regenerative medicine in fibrosis therapy
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Based on the cellular and molecular mechanisms underlying hepatic fibrogenesis, several kinds of approaches have been proposed to treat liver fibrosis. Among a number of growth factors and cytokines that regulate collagen metabolism, transforming growth factor (TGF)‐β is the most potent factor to accelerate liver fibrosis by activating hepatic stellate cells, stimulating collagen gene transcription, and suppressing matrix metalloproteinases expression. Thus, TGF‐β as well as its intracellular mediators, Smad proteins, can be potential therapeutic targets for liver fibrosis. Constitutive phosphorylation and nuclear accumulation of Smad3 is the common feature of activated stellate cells. We have synthesized a novel small compound that inhibits Smad3‐dependent collagen gene transcription by promoting nuclear import of a transcriptional repressor, YB‐1. Another insight into anti‐fibrotic strategies is the contribution of bone marrow‐derived cells to the regression of liver fibrosis. Administration of granulocyte‐colony stimulating factor enhanced the migration of bone marrow‐derived cells into fibrotic liver tissue and accelerated the regression of experimental liver fibrosis. We have recently identified novel unknown factors expressed by bone marrow‐derived cells that not only ameliorate liver fibrosis but also accelerate regeneration of fibrotic liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Higashiyama, R., Inagaki, Y., Hong, Y. Y., Kushida, M., Nakao, S., Niioka, M., Watanabe, T., Okano, H., Matsuzaki, Y., Shiota, G., et al. (2007) · Hepatology · doi:10.1002/hep.21477 · Cited by 261
Self-citation
Cited by
Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77958 · Cited by 351
Fathy, M., Okabe, M., Saad Eldien, H. M., & Yoshida, T. (2020) · Molecules · doi:10.3390/molecules25020348 · Cited by 44
Jang, Y. O., Kim, S. H., Cho, M.-Y., Kim, K. S., Park, K.-S., Cha, S.-K., Kim, M. Y., Chang, S. J., & Baik, S. K. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.067 · Cited by 29
Collagen-targeted molecular imaging in diffuse liver diseases
Zhou, I. Y., Tanabe, K. K., Fuchs, B. C., & Caravan, P. (2020) · Abdominal Radiology · doi:10.1007/s00261-020-02677-2 · Cited by 14
Metadata
- Authors
- Inagaki, Y., Higashiyama, R., & Higashi, K.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2012-02-09
- Volume
- 27
- Issue
- s2
- Pages
- 85-88
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W1607502514
- Cited by
- 43
- References
- 1
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel anti‐fibrotic modalities for liver fibrosis: Molecular targeting and regenerative medicine in fibrosis therapy. https://app.cochat.ai/papers/10.1111/j.1440-1746.2011.07006.x
- The paper
- Inagaki, Y., Higashiyama, R., & Higashi, K. (2012). Novel anti‐fibrotic modalities for liver fibrosis: Molecular targeting and regenerative medicine in fibrosis therapy. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/j.1440-1746.2011.07006.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.